Endometrial safety of continuous combined hormone replacement therapy with 17β-oestradiol (1 or 2 mg) and dydrogesterone

Maturitas

Volumn 37, Issue 3, 2001, Pages 191-199

  Bergeron, C ^a   Ferenczy, A ^b  

^a LABORATOIRE CERBA   (France)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

17 oestradiol; Dydrogesterone; Endometrium; Histology; Hormone replacement therapy

Indexed keywords

DYDROGESTERONE; ESTRADIOL;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLIMACTERIUM; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ENDOMETRIUM; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RISK BENEFIT ANALYSIS; SUBSTITUTION THERAPY;

EID: 0035977601     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(00)00176-6     Document Type: Article

References (27)

1. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues
2. Risk of localised and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens
3. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
4. The effects of estrogens and progestogens on the endometrium
5. Effect of long-term therapy with estrogen and progesterone on the endometrium of post-menopausal women
6. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer
7. Dydrogesterone has no peripheral (anti)-androgenic properties
8. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone
9. Safety of progestins: Effects of dydrogesterone on blood lipids
10. Progestins: A review of safety and tolerance in long-term administration
11. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer
12. Effect of dydrogesterone on the oestrogenized postmenopausal endometrium
13. Endometrial responses, side-effects and bleeding patterns in postmenopausal women using various doses of dydrogesterone in combination with conjugated oestrogens
14. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17β-oestradiol
15. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: Effect on calcium and lipid metabolism
16. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women
17. Benign diseases of the endometrium
18. Malignant lesions arising from benign endometrial polyps
19. Estrogen and progesterone receptor expression in endometrial polyps
20. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
21. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin intervention trial
22. Changes in the withdrawal bleeding pattern and endometrial histology during 17β-oestradiol-dydrogesterone therapy in post-menopausal women: A 2-year prospective study
23. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone
24. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens
25. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer
26. Risk of endometrial cancer following estrogen replacement with and without progestins